Pharmaceuticals company Marksans Pharma announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: Stood at Rs 8,407.96 million in Q1FY27, reflecting an increase of 35.61% compared to Rs 6,199.89 million in Q1FY26. On a QoQ basis, revenue decreased by 1.78% from Rs 8,561.14 million in Q4FY26. Total Income: For Q1FY27, the total income was Rs 8,662.00 million, up by 38.45% YoY from Rs 6,256.30 million in Q1FY26 and down by 2.81% QoQ from Rs 8,912.88 million in Q4FY26. EBITDA: Reached Rs 2,130.00 million in Q1FY27, marking a growth of 112.8% YoY compared to Rs 1,001.00 million in Q1FY26. It saw a 9.0% increase on a QoQ basis from Rs 1,954.00 million in Q4FY26. Profit After Tax (PAT): Reported at Rs 1,594.07 million in Q1FY27, a significant increase of 173.88% YoY from Rs 582.02 million in Q1FY26 and a 6.96% increase QoQ from Rs 1,490.32 million in Q4FY26. Earnings Per Share (EPS): Stood at Rs 3.47 in Q1FY27, up 169.0% YoY from Rs 1.29 in Q1FY26 and up 6.1% QoQ from Rs 3.27 in Q4FY26. Standalone Financial Highlights: Revenue from Operations: Stood at Rs 3,211.87 million in Q1FY27, an increase of 0.45% YoY compared to Rs 3,197.34 million in Q1FY26. Revenue declined by 11.17% QoQ from Rs 3,615.73 million in Q4FY26. Total Income: Reported at Rs 3,386.57 million in Q1FY27, up 5.26% YoY from Rs 3,217.44 million in Q1FY26 and down 12.95% QoQ from Rs 3,890.48 million in Q4FY26. Profit After Tax (PAT): Came in at Rs 690.37 million in Q1FY27, reflecting a growth of 43.66% YoY compared to Rs 480.56 million in Q1FY26. On a QoQ basis, PAT decreased by 24.90% from Rs 919.23 million in Q4FY26. Earnings Per Share (EPS): Stood at Rs 1.52 in Q1FY27, compared to Rs 1.06 in Q1FY26 (YoY growth of 43.40%) and Rs 2.03 in Q4FY26 (QoQ decline of 25.12%). Business Highlights Segment-wise Performance US & North America: This segment reported revenues of Rs 3,772.0 million in Q1FY27, growing 15.1% YoY but declining 7.1% QoQ. It remains the company's largest market, contributing approximately 45% of consolidated revenue. UK & Europe: Revenues reached Rs 3,560.0 million in Q1FY27, a substantial growth of 74.7% YoY and 15.7% QoQ. This region achieved its highest-ever quarterly revenue, aided by the acquisition of QliniQ. Australia & NZ: Reported revenues of Rs 876.0 million in Q1FY27, up 53.7% YoY but down 29.0% QoQ. Growth was driven by continued portfolio expansion and new product launches. Rest of World (ROW): Reported revenues of Rs 200.0 million in Q1FY27, down 36.8% YoY but up 6.0% QoQ. Performance in the Middle East was impacted by shipment delays. Other Business Updates Cash Position: The company crossed the Rs 10,000 million (Rs 1,000 crore) cash balance mark for the first time, closing Q1FY27 at Rs 10,580.0 million (Rs 1,058 crore). Acquisitions: Completed the 100% acquisition of QliniQ B.V. and ABCnow in Europe. QliniQ B.V. (Netherlands) contributed Rs 440.0 million (Rs 44 crore) in Q1FY27. R&D; Spends: Research & Development spending stood at Rs 230.0 million (Rs 23 crore) in Q1FY27, representing 2.8% of consolidated revenue. Working Capital: The working capital cycle improved to ~132 days in Q1FY27 from ~159 days in Q1FY26. Mark Saldanha, Managing Director of the Company, said, “Q1FY27 has been a strong start to the year, with an all-time high quarterly EBITDA of Rs 213 crore and PAT of Rs 159 crore, reflecting the strength of our underlying business and our continued focus on profitable growth. UK & Europe delivered their highest-ever quarterly revenue of Rs 356 crore, growing at 74.7% YoY. More importantly, Europe is emerging as a significant new growth engine for the Group, with the acquisition of QliniQ and the establishment of our front-end presence across the region. QliniQ contributed Rs 44 crore in Q1FY27, marking an important first step in our European expansion. We also crossed Rs 1,000 crore in cash balance for the first time, closing the quarter at Rs 1,058 crore, despite the recent acquisitions of QliniQ and ABCnow. This provides us with the financial strength and flexibility to continue investing in organic growth while pursuing calibrated inorganic opportunities. Looking ahead, our focus is clear: to carry this momentum forward, scale our businesses across geographies, accelerate new launches and further strengthen our European platform. We believe the combination of broad-based growth, expanding margins and a strong balance sheet positions Marksans well for the next phase of sustainable growth.” Result PDF